Page 6 - Davidb Weiner News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Davidb weiner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Davidb Weiner Today - Breaking & Trending Today

DNA vaccine candidate induces potent immunity, offers protective efficacy in non-human primate models

DNA vaccine candidate induces potent immunity, offers protective efficacy in non-human primate models
A synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV) developed at The Wistar Institute induced potent immune responses and afforded protective efficacy in non-human primate (NHP) models when given intradermally in abbreviated, low-dose immunization regimen.
A similar vaccine candidate was previously shown to be safe and tolerable with a three-dose intramuscular injection regimen in a recently completed human phase 1 study and is currently in expanded studies of phase 1/2a trial. New results were published today in
JCI Insight.
While several vaccine products are being advanced against MERS and other coronaviruses, low-dose delivery and shortened regimes are crucial to rapidly induce protective immunity, particularly during emerging outbreaks, as the current SARS-CoV-2 pandemic has emphasized. ....

Davidb Weiner , Emmal Reuschel , Emily Henderson , Vaccine Immunotherapy Center , Wistar Institute , Middle East , Wistar Executive Vice President , Charitable Trust Professor , Ami Patel , Caspar Wistar Fellow , எமிலி ஹென்டர்சன் , தடுப்பூசி நோயெதிர்ப்பு சிகிச்சை மையம் , நடுத்தர கிழக்கு , தொண்டு நம்பிக்கை ப்ரொஃபெஸர் , அமி படேல் ,

MERS DNA vaccine induces immunity, protects from virus challenge in preclinical model

The Wistar Institute
PHILADELPHIA (April 22, 2021) A synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV) developed at The Wistar Institute induced potent immune responses and afforded protective efficacy in non-human primate (NHP) models when given intradermally in abbreviated, low-dose immunization regimen. A similar vaccine candidate was previously shown to be safe and tolerable with a three-dose intramuscular injection regimen in a recently completed human phase 1 study and is currently in expanded studies of phase 1/2a trial.
New results were published today in JCI Insight.
“While several vaccine products are being advanced against MERS and other coronaviruses, low-dose delivery and shortened regimes are crucial to rapidly induce protective immunity, particularly during emerging outbreaks, as the current SARS-CoV-2 pandemic has emphasized,” said David B. Weiner, Ph.D., Wistar executive vice president, director of the ....

United States , Davidb Weiner , Emmal Reuschel , Vaccine Immunotherapy Center , Wistar Institute , Middle East , Charitable Trust Professor , Cancer Research , Ami Patel , Caspar Wistar Fellow , Middle East , Infectious Diseases , Infection Control , Vaccine Candidate , Immune Responses , Clinical Trials , Cancer Research , ஒன்றுபட்டது மாநிலங்களில் , தடுப்பூசி நோயெதிர்ப்பு சிகிச்சை மையம் , நடுத்தர கிழக்கு , தொண்டு நம்பிக்கை ப்ரொஃபெஸர் , புற்றுநோய் ஆராய்ச்சி , அமி படேல் ,

DARPA and JPEO-CBRND Award $37.6M to The Wistar Institute and Collaborators at INOVIO, ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
DARPA and JPEO-CBRND Award $37.6M to The Wistar Institute and Collaborators at INOVIO, .
The Wistar InstituteDecember 15, 2020 GMT
PHILADELPHIA, Dec. 15, 2020 (GLOBE NEWSWIRE)
A team of scientists from The Wistar Institute, INOVIO, AstraZeneca, the Perelman School of Medicine at the University of Pennsylvania, and Indiana University has received a $37.6 million award over two years from the Defense Advanced Research Projects Agency (DARPA) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for rapid preclinical development and translational studies of DNA-encoded monoclonal antibodies (DMAbs) as countermeasures for COVID-19. ....

United States , Indiana University , University Of Pennsylvania , Davidb Weiner , Pablo Tebas , Jesper Pallesen , Mark Esser , J Joseph Kim , Darien Sutton , National Cancer Institute , Head Of Microbial Sciences , Indiana University Research , Department Of Defense , Perelman School Of Medicine , Coalition For Epidemic Preparedness Innovations , Nuclear Defense , Defense Health Agency , Cancer Center , Program Executive Office For Chemical , Health Affairs , Vaccine Immunotherapy Center , Defense Advanced Research Projects Agency , Office Of The , Johns Hopkins Coronavirus Research Center , Wistar Institute , Perelman School ,

DARPA and JPEO-CBRND award $37.6M to The Wistar Institute and collaborators

Credit: The Wistar Institute
PHILADELPHIA (Dec. 15, 2020) A team of scientists from The Wistar Institute, INOVIO, AstraZeneca, the Perelman School of Medicine at the University of Pennsylvania, and Indiana University has received a $37.6 million award over two years from the Defense Advanced Research Projects Agency (DARPA) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for rapid preclinical development and translational studies of DNA-encoded monoclonal antibodies (DMAbs) as countermeasures for COVID-19.
DMAbs, unlike conventional therapeutic antibodies, are administered as genetic blueprints that instruct the patient s body to build its own highly specific antibodies against pathogens, such as bacteria and viruses, and as immunotherapeutics for cancer. Conceptually DMAbs have advantages over traditional monoclonal antibodies in scale-up and delivery, which would rapidly benefit large populations. ....

United States , University Of Pennsylvania , Davidb Weiner , Pablo Tebas , Jesper Pallesen , Mark Esser , J Joseph Kim , National Cancer Institute , Head Of Microbial Sciences , Department Of Defense , Perelman School Of Medicine , Coalition For Epidemic Preparedness Innovations , Nuclear Defense , Indiana University , Defense Health Agency , Cancer Center , Program Executive Office For Chemical , Health Affairs , Vaccine Immunotherapy Center , Defense Advanced Research Projects Agency , Office Of The , Johns Hopkins Coronavirus Research Center , Wistar Institute , Perelman School , Joint Program Executive Office , Charitable Trust Professor ,